Helix BioPharma Corp., a clinical-stage oncology company focused on developing therapies for difficult-to-treat cancers, has announced the appointment of Markus Loeffler, MD, MBA, as its new Chief Medical Officer (CMO). The move comes as the company prepares to enter a more execution-focused phase of clinical development, with several programs approaching key regulatory and clinical milestones.
Dr. Loeffler will lead the strategy and execution of Helix’s clinical programs, including the planned Phase Ib/II evaluation of L-DOS47 in combination with pembrolizumab for the first-line treatment of non-small cell lung cancer (NSCLC). He will also guide LEUMUNA™, a pre-IND oral immune checkpoint modulator, toward clinical development for leukemia relapse following allogeneic stem cell transplantation.
“I’ve had the privilege of working with Markus before, and I have seen firsthand his ability to translate innovative science into well-executed clinical development programs,” said Thomas Mehrling, MD, PhD, Chief Executive Officer of Helix. “He is an outstanding clinical development leader with a strong track record of advancing innovative oncology therapies through the development pathway. His expertise will be instrumental as we advance L-DOS47 into its next stage of clinical development and prepare LEUMUNA to enter the clinic.”
Dr. Loeffler brings more than three decades of leadership in oncology drug development to Helix. He has extensive experience advancing a broad range of therapeutics—including small molecules, biologics, antibody-drug conjugates (ADCs), radiopharmaceuticals, and immunotherapies—from early clinical development through Phase III and regulatory approval. Throughout his career, he has held senior clinical development and CMO roles at leading companies such as Roche, Advanced Accelerator Applications, Mundipharma, NH TherAguix, Corbus Pharmaceuticals, and SK Life Science. Notably, he led the pivotal Phase III clinical program for Lutathera®, which was subsequently approved for the treatment of certain gastroenteropancreatic neuroendocrine tumors.
“I’m excited to join Helix at such an important stage in its evolution,” said Dr. Loeffler. “The Company’s pipeline combines strong scientific foundations with clear clinical development opportunities. I am particularly enthused by the opportunity to advance L-DOS47 in combination with checkpoint inhibition and to bring LEUMUNA toward its first clinical evaluation. I look forward to working alongside the team to translate these programs into meaningful new treatment options for patients with difficult-to-treat cancers.”
The appointment of Dr. Loeffler comes at a critical juncture for Helix. The company’s pipeline is led by L-DOS47, a clinical-stage antibody-enzyme conjugate being developed as a combination therapy for NSCLC. Additional pipeline candidates include LEUMUNA™, a pre-IND oral immune checkpoint modulator for post-transplant leukemia relapse, and GEMCEDA™, a pre-IND gemcitabine prodrug for advanced solid tumors.
Helix BioPharma’s common shares are listed on the Toronto Stock Exchange (TSX: HBP), quoted on the OTC Pink Market (HBPCF), and listed on the Frankfurt Stock Exchange (FWB: HBP0). More information about the company and its pipeline can be found at https://www.helixbiopharma.com/.
This news reflects Helix’s commitment to advancing its oncology pipeline into later-stage clinical trials. With Dr. Loeffler’s leadership, the company aims to navigate the complex regulatory landscape and bring novel therapies to patients who currently have limited options. The success of these programs could not only transform the company’s trajectory but also offer new hope in the fight against notoriously difficult-to-treat cancers.
